Enveda raised $311 million in a Series E round led by Catalio Capital Management. New investors include Durable Capital Partners, ICONIQ, Lightspeed, and Surveyor Capital. Existing investors also participated. George Petrocheilos of Catalio joined Enveda’s board. The round follows two positive early clinical readouts in 2026. Proceeds will advance ENV-294, ENV-308, and ENV-6946 into later-stage trials. Additional medicines will enter clinical trials for inflammatory and metabolic conditions. The company will scale its PRISM AI platform. Total capital raised now exceeds $845 million.
What changed
Enveda had raised less than $534 million and had fewer clinical-stage programs.
What it unlocks
Advancing three medicines into later-phase trials and scaling the AI platform.
- $311 million Series E
- $845 million total raised
- 17 development candidates
- 3 in human trials
Sources